Artal Group S.A. Avidity Biosciences, Inc. Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$22.73 - $40.85 $14.9 Million - $26.8 Million	655,555 New	655,555 $26.8 Million
Q2 2023 Aug 11, 2023	SELL	$10.62 - $17.34 $2.25 Million - $3.68 Million	-211,962 Reduced 41.4%	300,000 $3.33 Million
Q1 2023 May 12, 2023	BUY	$15.35 - $25.65 $183,616 - $306,825	11,962 Added 2.39%	511,962 $7.86 Million
Q4 2022 Feb 13, 2023	BUY	$10.06 - $22.66 $2.52 Million - $5.67 Million	250,000 Added 100.0%	500,000 $11.1 Million
Q4 2021 Feb 11, 2022	BUY	$20.4 - $28.66 $2.19 Million - $3.08 Million	107,500 Added 75.44%	250,000 $5.94 Million
Q3 2020 Nov 13, 2020	SELL	$23.35 - $35.94 $758,875 - $1.17 Million	-32,500 Reduced 18.57%	142,500 $4.01 Million
Q2 2020 Aug 14, 2020	BUY	$26.62 - $31.5 $4.66 Million - $5.51 Million	175,000 New	175,000 $4.95 Million

252

107M

224K

161K

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.79B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.